A5089465499- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- BRCA gene mutations in cancer
- Monoclonal and Polyclonal Antibodies Research
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Medical Imaging Techniques and Applications
- Cancer Risks and Factors
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Esophageal Cancer Research and Treatment
- Cancer Cells and Metastasis
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
Samsung Medical Center
2015-2024
Sungkyunkwan University
2015-2024
Samsung (South Korea)
2005-2023
Seoul Medical Center
2020
Pfizer (United Kingdom)
2019
Bristol-Myers Squibb (Germany)
2019
AstraZeneca (Poland)
2019
Ono Pharmaceutical (United Kingdom)
2019
Janssen (Belgium)
2019
Eisai (Japan)
2019
The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 that inhibits dimerization, has a mechanism action is complementary to trastuzumab, and combination therapy two antibodies shown promising activity acceptable safety profile phase studies involving
The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations BRCA1 BRCA2 ( BRCA1/2).We conducted a randomized, open-label, phase 3 trial which BRCA1/2 mutation were assigned, 2:1 ratio, to receive (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, vinorelbine continuous 21-day cycles). primary end point was progression-free survival,...
Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer poor prognoses. The benefit adjuvant in these patients remains unclear.We randomly assigned 910 with HER2-negative (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either capecitabine without (control). primary end point was disease-free survival. Secondary points included overall...
Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2 (HER2) –targeted monoclonal antibodies, trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the properties of with cytotoxic activity DM1. T-DM1 demonstrated encouraging efficacy safety in a phase II study patients previously untreated HER2-positive metastatic breast cancer. Combination showed synergistic cell culture models had acceptable profile Ib study. Methods In MARIANNE study, 1,095...
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in neoadjuvant setting, but their role as adjuvant therapy remains uncertain. Methods In Adjuvant and/or Trastuzumab Treatment Optimization trial, patients with centrally confirmed early were randomly assigned to 1 year of T, L, sequence (T→L), or combination (L+T). The primary end point was disease-free survival...
In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2)-mutated advanced breast cancer (ABC). We report final overall (OS).This randomized phase III trial enrolled patients with gBRCA1/2-mutated HER2-negative ABC. Patients received or physician's choice of chemotherapy. OS was analyzed using stratified HR log-rank...
APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 1.00], P = .045) for patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), specifically those node-positive or hormone (HR)-negative disease. We now report the preplanned second interim overall (OS) descriptive updated IDFS analysis 74...
BackgroundThe optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double targeting approach steroidal anti-oestrogen fulvestrant in combination continued oestrogen deprivation.MethodsIn composite, multicentre, phase 3 randomised controlled done UK and South Korea, (oestrogen receptor [ER] positive, progesterone...
BackgroundResults from the phase III trial CLEOPATRA in human epidermal growth factor receptor 2-positive first-line metastatic breast cancer demonstrated significant improvements progression-free and overall survival with pertuzumab, trastuzumab, docetaxel over placebo, docetaxel. We carried out exploratory analyses of incidence time to development central nervous system (CNS) metastases patients CLEOPATRA.Patients methodsPatients received pertuzumab/placebo: 840 mg cycle 1, then 420 mg;...
Purpose This study aims to evaluate the impact of chemotherapy-induced alopecia (CIA) distress on body image, psychosocial well-being, and depression among breast cancer patients. Methods A cross-sectional survey was conducted at advocacy events held 16 hospitals in Korea. Alopecia assessed using 'Chemotherapy-Induced Distress Scale', image well-being were measured by European Organization for Research Treatment Cancer Quality Life Questionnaire Core 30 specific module (BR23), Center...
Accurate detection of genomic alterations using high-throughput sequencing is an essential component precision cancer medicine. We characterize the variant allele fractions (VAFs) somatic single nucleotide variants and indels across 5095 clinical samples profiled a custom panel, CancerSCAN. Our results demonstrate that significant fraction clinically actionable have low VAFs, often due to tumor purity treatment-induced mutations. The percentages mutations under 5% VAF hotspots in EGFR, KRAS,...
Abstract Purpose: Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall (OS) benefit in the phase III MONALEESA-7 trial of pre-/perimenopausal patients with hormone receptor (HR)-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). The median OS was not reached ribociclib arm protocol-specified final analysis; we hence performed an exploratory additional outcomes analysis extended follow-up (median, 53.5 months)....
Abstract Breast cancer (BC) in the Asia Pacific regions is enriched younger patients and rapidly rising incidence yet its molecular bases remain poorly characterized. Here we analyze whole exomes transcriptomes of 187 primary tumors from a Korean BC cohort (SMC) pre-menopausal perform systematic comparison with primarily Caucasian post-menopausal (TCGA). SMC harbors higher proportions HER2+ Luminal B subtypes, lower proportion A decreased ESR1 expression compared to TCGA. We also observe...
LBA1006 Background: Taselisib, a potent, selective PI3K inhibitor, has enhanced activity in PIK3CA-MUT BC cell lines and confirmed partial responses as single-agent or with FULV. We assessed taselisib + FULV pts ER-positive, HER2-negative, locally advanced MBC. Methods: SANDPIPER (NCT02340221) is double-blind, placebo (PBO)-controlled, randomized, phase III study. Postmenopausal disease recurrence progression during after an aromatase inhibitor were randomized 2:1 to receive (4 mg oral, qd)...
•Taselisib, a selective PI3K inhibitor, plus fulvestrant has clinical activity in PIK3CA-mutant, ER-positive breast cancer.•SANDPIPER (NCT02340221) assessed the efficacy of taselisib advanced cancer.•Taselisib had an expected safety profile, but with more discontinuations than placebo fulvestrant.•Taselisib versus significantly improved progression-free survival. BackgroundThe phase III SANDPIPER study (GDC-0032), potent, estrogen receptor-positive, HER2-negative, PIK3CA-mutant locally or...